AMRN Amarin Corporation plc Stock Quote

AMRN [NASD]

Index	-	P/E	461.82	EPS (ttm)	0.01	Insider Own	1.20%	Shs Outstand	395.90M	Perf Week	-3.61%
Market Cap	2.01B	Forward P/E	-	EPS next Y	-0.10	Insider Trans	-2.16%	Shs Float	380.97M	Perf Month	-6.10%
Income	4.30M	PEG	11.87	EPS next Q	-0.03	Inst Own	34.00%	Short Float	4.32%	Perf Quarter	8.09%
Sales	620.40M	P/S	3.25	EPS this Y	28.70%	Inst Trans	-7.55%	Short Ratio	4.36	Perf Half Y	-19.37%
Book/sh	1.63	P/B	3.12	EPS next Y	-100.00%	ROA	0.40%	Target Price	-	Perf Year	21.82%
Cash/sh	1.28	P/C	3.96	EPS next 5Y	38.90%	ROE	0.70%	52W Range	3.36 - 9.25	Perf YTD	3.89%
Dividend	-	P/FCF	-	EPS past 5Y	43.60%	ROI	-3.30%	52W High	-45.08%	Beta	2.27
Dividend %	-	Quick Ratio	2.00	Sales past 5Y	49.70%	Gross Margin	79.30%	52W Low	51.19%	ATR	0.23
Employees	1000	Current Ratio	2.70	Sales Q/Q	14.20%	Oper. Margin	1.20%	RSI (14)	44.21	Volatility	3.33% 3.88%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	75.80%	Profit Margin	0.70%	Rel Volume	1.06	Prev Close	5.15
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Aug 05 BMO	Payout	0.00%	Avg Volume	3.77M	Price	5.08
Recom	2.30	SMA20	-5.88%	SMA50	3.45%	SMA200	-6.90%	Volume	4,137,591	Change	-1.36%

May-12-21

Downgrade

Goldman

Neutral → Sell

$6 → $5

Sep-29-20

Resumed

JP Morgan

Neutral

Aug-26-20

Initiated

Piper Sandler

Overweight

$21

May-05-20

Initiated

Northland Capital

Outperform

$15

Mar-31-20

Upgrade

Oppenheimer

Underperform → Perform

Mar-31-20

Downgrade

Jefferies

Buy → Hold

$30 → $4

Mar-31-20

Downgrade

Goldman

Buy → Neutral

Mar-13-20

Upgrade

Goldman

Neutral → Buy

$28

Mar-02-20

Initiated

Cowen

Outperform

$23

Feb-18-20

Upgrade

Citigroup

Neutral → Buy

$27 → $24

Jan-06-20

Initiated

JP Morgan

Neutral

$22

Dec-16-19

Downgrade

Stifel

Buy → Hold

Nov-20-19

Initiated

Oppenheimer

Underperform

Nov-18-19

Downgrade

Citigroup

Buy → Neutral

Nov-15-19

Reiterated

SVB Leerink

Outperform

$26 → $29

Oct-31-19

Initiated

Aegis Capital

Buy

$23

Oct-15-19

Initiated

Goldman

Neutral

$17

Aug-14-19

Initiated

SVB Leerink

Outperform

$26

Jul-09-19

Reiterated

Jefferies

Buy

$30

Jun-17-19

Initiated

ROTH Capital

Buy

$31

Sep-13-21 07:00AM	Amarin Announces First European Launch of VAZKEPA (icosapent ethyl) in Germany GlobeNewswire
06:00AM	Amarin to Participate in September Investment Conferences GlobeNewswire
Sep-08-21 06:06AM	5 Stocks With 195% to 467% Upside, According to Wall Street Motley Fool
Aug-31-21 07:00AM	Amarin Reports Overview of Latest Clinical Research Evaluating VASCEPA®/VAZKEPA (Icosapent Ethyl) and Eicosapentaenoic Acid (EPA) Presented at ESC Congress 2021, Organized by the European Society of Cardiology GlobeNewswire
Aug-23-21 03:15AM	Amarin Reports Data from REDUCE-IT® Showing VASCEPA®/VAZKEPA (Icosapent Ethyl) Significantly Reduces Ischemic Events in Patients with Prior Heart Attacks Presented in Late Breaking Science Session at ESC Congress 2021, Organized by the European Society of Cardiology GlobeNewswire +7.24%
Aug-16-21 07:00AM	Latest Clinical Research Evaluating VASCEPA®/VAZKEPA (Icosapent Ethyl) in Patients with Residual Cardiovascular Risk to be Presented at ESC Congress 2021, Organized by the European Society of Cardiology GlobeNewswire
Aug-07-21 03:29AM	Amarin Corporation plc's (NASDAQ:AMRN) Stock Is Going Strong: Have Financials A Role To Play? Simply Wall St.
Aug-06-21 10:12AM	Amarin (AMRN) Q2 Earnings Top, Vascepa Strong Despite Generics Zacks
Aug-05-21 02:34PM	Why Amarin Is Soaring Today Motley Fool +9.46%
12:00PM	Amarin (AMRN) Q2 2021 Earnings Call Transcript Motley Fool
06:00AM	Amarin Reports Second Quarter and Six Month 2021 Financial Results and Provides Business Update GlobeNewswire
Aug-03-21 09:59AM	What's in the Cards for Amarin (AMRN) This Earnings Season? Zacks
Jul-19-21 12:50PM	Is Amarin Corporation plc (AMRN) Going to Burn These Hedge Funds? Insider Monkey
Jul-15-21 06:35AM	Amarin to Report Second Quarter and Six Month 2021 Financial Results and Host Conference Call on August 5, 2021 GlobeNewswire
Jun-22-21 06:13PM	Why Amarin Fell Again Today Motley Fool
Jun-21-21 11:30AM	Why Amarin Stock Is Sinking Today Motley Fool -5.24%
09:51AM	UPDATE 1-U.S. Supreme Court denies Amarin's bid to revive Vascepa drug patents Reuters
09:31AM	U.S. Supreme Court denies Amarin's bid to revive Vascepa drug patents Reuters
Jun-02-21 04:30PM	Further Insights into Mechanism of Action of Icosapent Ethyl and Its Unique Form of Eicosapentaenoic Acid (EPA) Presented at the European Atherosclerosis Society (EAS) Congress 2021 GlobeNewswire
May-18-21 06:19PM	Why Amarin Trounced the Market on Tuesday Motley Fool +5.09%
06:05AM	Amarin to Present at Two Investor Conferences in June 2021 GlobeNewswire
May-17-21 04:05PM	Amarin Highlights Multiple Scientific Findings for VASCEPA® (Icosapent Ethyl) and Its Unique Active Ingredient at the American College of Cardiologys 70th Annual Scientific Session GlobeNewswire
May-15-21 08:00AM	REDUCE-IT® Heart Failure Analyses by VASCEPA® (Icosapent Ethyl)-Driven Serum Eicosapentaenoic Acid (EPA) Levels Suggest Potential Benefit in New Heart Failure in Studied At-Risk Patients as Presented at the American College of Cardiologys 70th Annual Scientific Session GlobeNewswire
May-12-21 11:03AM	Why Amarin Stock Is Tumbling Today Motley Fool -5.64%
May-04-21 07:00AM	Clinical Data and Other Research Results Regarding VASCEPA® (Icosapent Ethyl) and Its Unique Active Ingredient to Be Presented at the American College of Cardiologys 70th Annual Scientific Session GlobeNewswire
Apr-29-21 08:01PM	Amarin (AMRN) Q1 2021 Earnings Call Transcript Motley Fool
12:00PM	Amarin (AMRN) Q1 Earnings Top, Vascepa Sales Hit by COVID-19 Zacks
06:10AM	Amarin Reports First Quarter 2021 Financial Results and Provides Business Update GlobeNewswire
06:00AM	Amarin Announces Planned Retirement of Joseph T. Kennedy, EVP, General Counsel GlobeNewswire
Apr-26-21 09:49AM	Is AMRN Stock A Buy or Sell? Insider Monkey
Apr-22-21 10:53AM	Amarin Receives Great Britain Marketing Authorization for VAZKEPA from the Medicines and Healthcare Products Regulatory Agency (MHRA) 1,2 GlobeNewswire
Apr-21-21 01:18PM	Billionaire Steve Cohens Top 10 Small-Cap Stock Picks Insider Monkey
Apr-20-21 06:05AM	Amarin to Report First Quarter Results and Host Conference Call on April 29, 2021 GlobeNewswire
Apr-17-21 09:50AM	VASCEPA® (Icosapent Ethyl) Reported to Impact Vulnerable Coronary Plaque Features in New Analyses of EVAPORATE Study Presented as Late-Breaking Science at ESC Preventive Cardiology 2021 GlobeNewswire
Apr-15-21 10:45AM	The Technical Condition of Amarin Corp. Remains Weak TheStreet.com
Apr-13-21 03:05PM	Amarin: Could the New CEO Help Vazkepas European Push? TipRanks -13.01%
11:39AM	Why Amarin Stock Is Sinking Today Motley Fool
08:14AM	The Daily Biotech Pulse: Leadership Transition At Amarin, Vaccine Setback For J&J, FDA Nod For Label Expansion of Roche's Asthma Drug Benzinga
08:01AM	Amarin Slumps as CEO Plans to Retire in August TheStreet.com
Apr-12-21 04:30PM	Amarin Announces CEO Succession Plan GlobeNewswire
Apr-10-21 06:40AM	3 Top Healthcare Stocks to Buy in April Motley Fool
Apr-09-21 07:33AM	Should You Buy Amarin in April? Motley Fool
01:23AM	Amarin Corporation plc (NASDAQ:AMRN) Shares Could Be 43% Below Their Intrinsic Value Estimate Simply Wall St.
Apr-06-21 06:05AM	Amarin Commences Commercial Initiatives for VAZKEPA in European Union Following Recent Regulatory Approval for Cardiovascular Risk Reduction Indication GlobeNewswire
Apr-01-21 06:22AM	2 Great Stocks Under $10 per Share Motley Fool
Mar-30-21 05:22PM	Why Amarin Stock Was a Winner Today Motley Fool
08:06AM	The Daily Biotech Pulse: Wave Life Sciences Pulls Plug On 2 Assets, Amarin's Vascepa Snags European Approval, Biocept Jumps On Earnings Benzinga
07:16AM	Amarin Stock Is Trading Higher After EU Approval For Icosapent Ethyl Benzinga
06:24AM	Amarin Receives European Commission (EC) Approval for VAZKEPA to Reduce Cardiovascular Risk GlobeNewswire
Mar-29-21 07:28AM	Amarin's Vascepa Recommended By Canadian Cardiovascular Society For Prevention Of Cardiovascular Diseases Benzinga
07:00AM	Fifteen Medical Societies Now Recommend Icosapent Ethyl to Reduce Cardiovascular Risk, Further Supporting that VASCEPA® is Rapidly Becoming a New Standard of Care GlobeNewswire
Mar-17-21 11:30AM	VASCEPA® (Icosapent Ethyl) Found in Prespecified and Post Hoc Analyses to Significantly Reduce Stroke in At-Risk Patients in Analyses of Landmark REDUCE-IT® Study Presented at International Stroke Conference 2021 GlobeNewswire
Mar-09-21 11:41PM	Did Amarin Corporation plc (NASDAQ:AMRN) Insiders Buy Up More Shares? Simply Wall St. +7.60%
Mar-01-21 08:00AM	Amarin (AMRN) Q4 2020 Earnings Call Transcript Motley Fool -8.16%
Feb-26-21 09:47AM	Amarin (AMRN) Q4 Earnings & Revenues Top, Vascepa Sales Solid Zacks
Feb-25-21 11:21AM	How Amarin Beat Wall Street's Q4 Estimates Motley Fool
05:55AM	Amarin Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update GlobeNewswire
Feb-18-21 06:05AM	Amarin to Present at Two Upcoming Investor Conferences GlobeNewswire
Feb-17-21 08:05AM	Amarin to Report Fourth Quarter and Full Year 2020 Results and Host Conference Call on February 25, 2021 GlobeNewswire
Feb-09-21 07:00PM	Why Amarin Rose as Much as 7.9% Today Motley Fool
07:00AM	Amarin Provides Update on VASCEPA® (Icosapent Ethyl) Regulatory Review Processes in Mainland China and Hong Kong GlobeNewswire
Feb-07-21 11:27PM	Rock star Growth Puts Amarin (NASDAQ:AMRN) In A Position To Use Debt Simply Wall St.
Feb-01-21 06:25PM	Why Amarin Corporation Shot 7.7% Higher Today Motley Fool +7.73%
Jan-29-21 12:52PM	Amarin Receives Positive CHMP Opinion for Icosapent Ethyl for Cardiovascular Risk Reduction GlobeNewswire
Jan-26-21 08:07AM	The Daily Biotech Pulse: Novartis Misses, J&J Beats In Big Pharma Earnings, Vaccine Developer CureVac Taps Equity Market Benzinga
Jan-25-21 07:35PM	Amarin Expands Cardiovascular Risk Reduction Patent Infringement Lawsuit to Include Health Care Insurance Provider GlobeNewswire +15.42%
Jan-24-21 06:08AM	3 Stocks Wall Street Thinks Will Soar 50% or More in 2021 Motley Fool
Jan-22-21 07:22AM	The Daily Biotech Pulse: Fluidigm's Saliva-Based COVID Test Approved In Europe, China Backs Amarin's Vascepa Benzinga
Jan-21-21 04:30PM	Icosapent Ethyl Included in the Chinese Society of Cardiology (CSC) Updated Guidelines for Primary Prevention of Cardiovascular Diseases GlobeNewswire
Jan-09-21 01:36AM	Amarin Corporation plc's (NASDAQ:AMRN) About To Shift From Loss To Profit Simply Wall St.
Jan-07-21 06:05AM	Amarin Provides Preliminary 2020 Results and 2021 Outlook GlobeNewswire +9.69%
Jan-05-21 09:32AM	This Stock Could Be a Surprise Growth Pick for 2021 Motley Fool
Jan-04-21 06:05AM	Amarin to Present at 39th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-31-20 08:46AM	Amarin (AMRN) Surges: Stock Moves 9% Higher Zacks -6.50%
Dec-21-20 09:41AM	Is AMRN A Good Stock To Buy According To Hedge Funds? Insider Monkey
Dec-14-20 05:00AM	Amarin Highlights Multiple VASCEPA® (Icosapent Ethyl)-Related Scientific Findings Presented at National Lipid Association (NLA) Scientific Sessions 2020, Including First COVID-19 Clinical Results GlobeNewswire
Dec-12-20 09:30PM	Amarin Reports Encouraging Efficacy and Safety Results from Pilot Study Treating COVID-19 Infected Outpatients with VASCEPA® (Icosapent Ethyl) in Late Breaker Presentation at National Lipid Association (NLA) Scientific Sessions 2020 GlobeNewswire
Dec-11-20 10:01AM	Is the Options Market Predicting a Spike in Amarin (AMRN) Stock? Zacks
Dec-07-20 07:00AM	VASCEPA® (Icosapent Ethyl)-Related Scientific Findings to Be Presented at National Lipid Association (NLA) Scientific Sessions 2020 GlobeNewswire
Dec-06-20 11:41PM	The Amarin (NASDAQ:AMRN) Share Price Is Up 168% And Shareholders Are Boasting About It Simply Wall St.
Dec-01-20 08:08AM	The Daily Biotech Pulse: Pfizer, BioNTech File Marketing Application In Europe, NuCana Jumps On Data, Amarin Takes On Hikma In Patent Lawsuit Benzinga
Nov-30-20 07:55PM	Amarin Files Patent Infringement Lawsuit Against Hikma GlobeNewswire +7.83%
Nov-24-20 06:05AM	Amarin to Present at Piper Sandlers 32nd Annual Healthcare Conference (Virtual) GlobeNewswire
Nov-22-20 06:28AM	Amarin vs. the Generics: Who Will Win? Motley Fool
Nov-20-20 10:20AM	ROCE Insights For Amarin Corp Benzinga
10:06AM	Amarin Jumps on Heart-Drug Progress in China Trial TheStreet.com
07:37AM	The Daily Biotech Pulse: Amarin Surges On Vascepa Data, Mesoblast Rallies On Novartis Deal, Decision Day For Eiger Benzinga
Nov-19-20 06:30PM	Amarin Shares Topline Data from Partners Pivotal Phase 3 Study of VASCEPA® (Icosapent Ethyl) in Mainland China GlobeNewswire
Nov-18-20 07:00AM	Multiple New VASCEPA® (Icosapent Ethyl)-Related Scientific Findings Presented at American Heart Associations Virtual Scientific Sessions 2020 GlobeNewswire
Nov-13-20 10:00AM	VASCEPA® (Icosapent Ethyl) Found to Significantly Reduce Ischemic Events in Patients with Prior Coronary Artery Bypass Grafting (CABG) Procedures in Post Hoc Subgroup Analyses of Landmark REDUCE-IT® Study Presented at American Heart Associations Virtual Scientific Sessions 2020 GlobeNewswire +5.94%
Nov-11-20 04:30PM	Amarin to Present at the Stifel 2020 Virtual Healthcare and Jefferies Virtual London Healthcare Conferences GlobeNewswire
Nov-09-20 06:58PM	Good Entry Point for Amarin Stock? Not Just Yet, Says Analyst TipRanks
Nov-06-20 10:39AM	Amarin's (AMRN) Q3 Earnings Lag, Sales In Line, Stock Down Zacks -5.10%
Nov-05-20 09:01PM	Amarin (AMRN) Q3 2020 Earnings Call Transcript Motley Fool -9.62%
09:12AM	Looking Into Amarin Corp's Return On Capital Employed Benzinga
08:54AM	Amarin Corp: Q3 Earnings Insights Benzinga
06:00AM	Amarin Reports Third Quarter 2020 Financial Results and Provides Business Update GlobeNewswire
05:30AM	Are Institutions Heavily Invested In Amarin Corporation plc's (NASDAQ:AMRN) Shares? Simply Wall St.
Oct-29-20 07:00AM	New VASCEPA® (Icosapent Ethyl)-Related Scientific Findings to Be Presented at American Heart Associations Virtual Scientific Sessions 2020 GlobeNewswire
Oct-26-20 05:00PM	Amarin's Vascepa Shows Reduced Cardiovascular Events in Kidney Patients in Latest Study Motley Fool

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, and eicosapentaenoic acid. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kalb Michael Wayne	SVP and CFO	Aug 12	Option Exercise	2.35	120,000	281,800	325,010	Aug 13 08:04 PM
Kalb Michael Wayne	SVP and CFO	Aug 12	Sale	5.25	120,000	630,240	205,010	Aug 13 08:04 PM
STACK DAVID M	Director	Jun 04	Buy	4.54	10,000	45,350	40,000	Jun 07 09:53 PM
STACK DAVID M	Director	Jun 03	Buy	4.62	5,000	23,115	30,000	Jun 07 09:53 PM
Ketchum Steven B	Chief Scientific Officer	Feb 01	Option Exercise	2.53	192,358	485,882	600,724	Feb 03 08:02 PM
Ketchum Steven B	Chief Scientific Officer	Feb 01	Sale	8.06	217,728	1,754,134	382,996	Feb 03 08:02 PM
Ketchum Steven B	Chief Scientific Officer	Jan 27	Option Exercise	2.75	278,237	764,566	809,741	Jan 29 08:03 PM
Ketchum Steven B	Chief Scientific Officer	Jan 27	Sale	8.01	421,629	3,378,131	388,112	Jan 29 08:03 PM
STACK DAVID M	Director	Nov 30	Buy	4.86	25,000	121,517	25,000	Dec 02 08:05 PM
THERO JOHN F	President and CEO	Nov 11	Sale	4.07	413,565	1,681,183	2,739,000	Nov 12 08:01 PM
THERO JOHN F	President and CEO	Nov 10	Option Exercise	3.40	615,261	2,091,887	3,306,405	Nov 12 08:01 PM
THERO JOHN F	President and CEO	Nov 10	Sale	4.13	153,840	635,975	3,152,565	Nov 12 08:01 PM
THERO JOHN F	President and CEO	Nov 09	Option Exercise	3.40	134,739	458,113	2,691,144	Nov 12 08:01 PM
Zakrzewski Joseph S	Director	Oct 21	Option Exercise	3.40	100,000	340,000	184,547	Oct 22 08:03 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience